Danuglipron: The Rise and Fall of Pfizer's Oral GLP-1 — And What It Teaches Us

Pfizer's danuglipron was once the company's highest-profile pipeline asset — an oral small-molecule GLP-1 agonist that could have competed head-to-head with Novo Nordisk and Eli Lilly in the weight-loss market. On April 14, 2025, Pfizer killed it. The story of danuglipron's failure is essential context for understanding why Foundayo's success was never guaranteed.^1,4

Phase 2b: Promising Efficacy, Devastating Tolerability

In December 2023, Pfizer released Phase 2b results for twice-daily danuglipron in adults with obesity. The efficacy numbers were competitive: placebo-adjusted weight reductions of 8% to 13% at 32 weeks, depending on dose.^1,2

But the tolerability data was disqualifying. Discontinuation rates exceeded 50% across all dose groups — compared to approximately 40% with placebo. The most common adverse events were gastrointestinal (nausea, vomiting, diarrhea), consistent with the GLP-1 class, but at rates high enough that more than half of patients couldn't stay on the drug long enough to benefit.¹

The Once-Daily Reformulation Gamble

Rather than abandon the molecule entirely, Pfizer pivoted. In July 2024, the company announced it would advance a once-daily reformulation, hypothesizing that less frequent dosing might improve tolerability. The dose-optimization studies (NCT06567327, NCT06568731) met their pharmacokinetic objectives — confirming that a formulation and dose existed with competitive potential.³

But in April 2025, Pfizer pulled the plug anyway. The reason: a single participant in the dose-optimization studies experienced potential drug-induced liver injury (DILI), which resolved after discontinuing the drug. While no participant experienced liver failure or required treatment, and the overall frequency of liver enzyme elevations was "in-line with approved agents in the class," the DILI signal, combined with the competitive landscape, made the risk-reward calculus untenable.⁴

The Competitive Coffin Nail

By April 2025, Pfizer's competitive window had closed. Eli Lilly's orforglipron (Foundayo) was already showing cleaner Phase 2 data with once-daily dosing and no fasting requirement. Novo Nordisk's oral Wegovy pill had been approved in December 2025. Entering Phase 3 with a molecule that had a 50%+ dropout rate in its original formulation and a DILI signal in the reformulation — against two approved competitors — was not commercially rational.^5,6

Pfizer also discontinued a second GLP-1 candidate (lotiglipron) due to liver safety signals, and a third (PF-06954522) was dropped after Phase 1 review. The company's entire internal GLP-1 portfolio was wiped out, leaving only PF-07976016, a GIPR antagonist in Phase 2.⁵

What Danuglipron Teaches Us

Three lessons are important for interpreting the broader GLP-1 pipeline:

1. Small-molecule oral GLP-1 is genuinely hard. Pfizer, one of the world's largest pharmaceutical companies, spent years and billions on oral GLP-1 development and failed. Lilly's Foundayo succeeding was not inevitable — it reflects a specific molecular design achievement.

2. Tolerability is the real bottleneck. GLP-1 efficacy is relatively achievable. The challenge is getting patients to tolerate the drug long enough to benefit. Danuglipron's 50%+ dropout rate would have made real-world effectiveness far lower than trial efficacy.

3. First-mover advantage matters. Foundayo and oral Wegovy's head start means any late entrant needs to show clearly superior efficacy or tolerability — not just competitive data.